0001209191-20-049421.txt : 20200903 0001209191-20-049421.hdr.sgml : 20200903 20200903164239 ACCESSION NUMBER: 0001209191-20-049421 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200902 FILED AS OF DATE: 20200903 DATE AS OF CHANGE: 20200903 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kulkarni Samarth CENTRAL INDEX KEY: 0001682019 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37923 FILM NUMBER: 201159670 MAIL ADDRESS: STREET 1: C/O CRISPR THERAPEUTICS AG STREET 2: 200 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CRISPR Therapeutics AG CENTRAL INDEX KEY: 0001674416 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 473173478 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: BAARERSTRASSE 14 CITY: ZUG STATE: V8 ZIP: CH-6300 BUSINESS PHONE: 6173154600 MAIL ADDRESS: STREET 1: BAARERSTRASSE 14 CITY: ZUG STATE: V8 ZIP: CH-6300 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-09-02 0 0001674416 CRISPR Therapeutics AG CRSP 0001682019 Kulkarni Samarth C/O CRISPR THERAPEUTICS, INC. 610 MAIN STREET CAMBRIDGE MA 02139 1 1 0 0 Chief Executive Officer Common Shares 2020-09-02 4 F 0 779 94.15 D 169968 D On December 1, 2017, the reporting person was granted 26,667 restricted stock units. On September 1, 2020, 1,667 restricted stock units vested. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. /s/ Michael Esposito, attorney-in-fact 2020-09-03